Landmark analyses of PFS regardless of treatment received. Landmark analysis based on MRD kinetics from randomization to (A) 14 months and (B) 28 months, regardless of ixazomib or placebo treatment in the TOURMALINE-MM3 and -MM4 trials. inf, infinity; NR, not reached. ∗HR, of MRD⁻ to MRD⁺ vs sustained MRD⁻ unstable due to small event numbers.